• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年急性髓系白血病(AML)和高危骨髓增生异常综合征(MDS)患者造血干细胞移植(HSCT)中减低强度预处理(RIC)方案的前瞻性可行性分析

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

作者信息

Estey Elihu, de Lima Marcos, Tibes Raoul, Pierce Sherry, Kantarjian Hagop, Champlin Richard, Giralt Sergio

机构信息

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

出版信息

Blood. 2007 Feb 15;109(4):1395-400. doi: 10.1182/blood-2006-05-021907. Epub 2006 Oct 12.

DOI:10.1182/blood-2006-05-021907
PMID:17038533
Abstract

To prospectively assess the applicability of reduced-intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 years or older with acute myeloid leukemia (AML) and unfavorable cytogenetics would be evaluated during induction for a possible RIC-HSCT in first complete remission (CR1). Ninety-nine of 259 patients entered CR. Fifty-three of the 99 were seen by the Transplant Service with the remainder not seen because of illness, lack/unavailability of siblings, refusal, or, primarily, unclear reasons (21 patients). A donor was identified for 26 patients (21 sibling, 5 unrelated) with RIC-HSCT performed in 14 (13 sibling). Results in consulted patients suggested that 50% or fewer of the 85 patients who did not undergo transplantation were potential transplant candidates. We attempted to find one or more chemotherapy pair-mates for each patient who underwent transplantation based on cytogenetics, age, and a relapse-free survival (RFS) time that was more than or equal to the time from CR1 to RIC-HSCT in the patient who underwent transplantation. Thirty-two of the 39 matches favored (longer RFS) RIC-HSCT and 7, chemotherapy. The probability that the corresponding beta distribution was different than expected (ie, that RIC-HSCT was superior) was 0.99 (P=.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability.

摘要

为前瞻性评估减低强度预处理造血干细胞移植(RIC-HSCT)的适用性,我们制定了一项方案,即对所有年龄在50岁及以上、患有急性髓系白血病(AML)且细胞遗传学预后不良的未治疗患者,在诱导缓解期评估其是否有可能在首次完全缓解(CR1)时接受RIC-HSCT。259例患者中有99例进入CR。99例中的53例由移植科会诊,其余患者因疾病、缺乏/没有同胞供者、拒绝,或主要因不明原因(21例患者)而未会诊。为26例患者找到了供者(21例同胞供者,5例无关供者),其中14例(13例同胞供者)接受了RIC-HSCT。会诊患者的结果表明,85例未接受移植的患者中,潜在移植候选者不到50%。我们试图根据细胞遗传学、年龄以及无复发生存期(RFS)时间,为每例接受移植的患者找到一个或多个化疗配对伙伴,该RFS时间应大于或等于接受移植患者从CR1到RIC-HSCT的时间。39例配对中,32例倾向于(RFS更长)RIC-HSCT,7例倾向于化疗。相应的贝塔分布与预期不同(即RIC-HSCT更优)的概率为0.99(P = 0.004)。生存方面的结果相似。因此,虽然RIC-HSCT似乎值得关注,但需要方法来扩大其适用性。

相似文献

1
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).老年急性髓系白血病(AML)和高危骨髓增生异常综合征(MDS)患者造血干细胞移植(HSCT)中减低强度预处理(RIC)方案的前瞻性可行性分析
Blood. 2007 Feb 15;109(4):1395-400. doi: 10.1182/blood-2006-05-021907. Epub 2006 Oct 12.
2
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
3
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.马利兰剂量强度与骨髓增生异常综合征或急性髓系白血病患者行减低强度异基因外周血造血干细胞移植的结局。
Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.
4
[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].[减低强度预处理异基因造血干细胞移植治疗骨髓增生异常综合征的研究进展 - 综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):969-74.
5
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.阿扎胞苷桥接后行异基因造血干细胞移植治疗高危骨髓增生异常综合征和低原始细胞数急性髓系白血病的可行性:BMT-AZA 前瞻性研究结果。
Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154.
6
Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.优化造血干细胞移植在老年骨髓增生异常综合征患者中的应用。
Curr Opin Hematol. 2013 Mar;20(2):150-6. doi: 10.1097/MOH.0b013e32835d8e8e.
7
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.预处理强度对T细胞充足的单倍体相合干细胞移植治疗急性白血病的影响:欧洲血液与骨髓移植协会急性白血病工作组的报告
J Hematol Oncol. 2016 Mar 15;9:25. doi: 10.1186/s13045-016-0248-3.
8
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.强度调节的困境:清髓性调节如何改善异基因造血细胞移植的结局。
Biol Blood Marrow Transplant. 2019 Mar;25(3):606-612. doi: 10.1016/j.bbmt.2018.09.012. Epub 2018 Sep 19.
9
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.40岁以上急性髓性白血病患者接受减低剂量预处理后的造血干细胞移植。
Biol Blood Marrow Transplant. 2008 Feb;14(2):181-6. doi: 10.1016/j.bbmt.2007.09.017. Epub 2007 Dec 31.
10
Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor.异基因造血干细胞移植后采用减低强度预处理方案行原供者二次移植治疗白血病复发。
Am J Hematol. 2013 Jun;88(6):485-91. doi: 10.1002/ajh.23439. Epub 2013 May 2.

引用本文的文献

1
A Clinically Relevant Mouse Model of Reduced-Intensity Conditioning for Allogeneic HLA-Identical Hematopoietic Stem Cell Transplantation.一种用于同种异体 HLA 匹配造血干细胞移植的低强度预处理的临床相关小鼠模型。
Methods Mol Biol. 2025;2907:161-181. doi: 10.1007/978-1-0716-4430-0_8.
2
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.前瞻性分析急性白血病患者异基因造血细胞移植的障碍。
Am J Hematol. 2023 Dec;98(12):1869-1876. doi: 10.1002/ajh.27084. Epub 2023 Sep 9.
3
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.
自体移植后 PD-1 阻断治疗不适合异体移植的 AML 患者的 2 期研究。
Blood Adv. 2023 Sep 26;7(18):5215-5224. doi: 10.1182/bloodadvances.2023010477.
4
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.老年急性髓系白血病患者(包括异基因造血干细胞移植)的演变趋势和结局。
Am J Hematol. 2023 Sep;98(9):1383-1393. doi: 10.1002/ajh.26997. Epub 2023 Jun 19.
5
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.老年急性髓系白血病微移植专家共识——国际微移植兴趣小组报告
Heliyon. 2023 Mar 31;9(4):e14924. doi: 10.1016/j.heliyon.2023.e14924. eCollection 2023 Apr.
6
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.在 Connect®髓系疾病登记处的学术和社区站点中,新发高危骨髓增生异常综合征和急性髓系白血病患者的移植转诊模式:潜在的护理障碍。
Transplant Cell Ther. 2023 Jul;29(7):460.e1-460.e9. doi: 10.1016/j.jtct.2023.04.011. Epub 2023 Apr 21.
7
Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors.通过与白血病护理和半相合供者整合,改善 HCT 的可及性,减少种族差异。
Blood Adv. 2023 Aug 8;7(15):3816-3823. doi: 10.1182/bloodadvances.2023009765.
8
Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.异基因移植治疗急性髓细胞白血病:综合性单机构经验
Haematologica. 2023 Sep 1;108(9):2369-2379. doi: 10.3324/haematol.2023.282729.
9
Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia.老年急性髓系白血病患者异基因造血干细胞移植的现状与展望。
Stem Cells Transl Med. 2022 May 27;11(5):461-477. doi: 10.1093/stcltm/szac015.
10
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.年龄不是 AML 处于 CR1 期行 HCT 成人的障碍:当代 CIBMTR 分析。
Bone Marrow Transplant. 2022 Jun;57(6):911-917. doi: 10.1038/s41409-022-01650-5. Epub 2022 Apr 2.